This article is more than 5 years old. Information may no longer be current.
TAVR 15th anniversary celebrated with 10 notable stories from 2017
Click Here to Manage Email Alerts
Transcatheter aortic valve replacement, a minimally invasive procedure for treatment of patients with aortic stenosis, was first performed in 2002 by Alain Cribier, MD, and colleagues. It has enabled AVR to occur in patients who were too high-risk for surgery, and is on its way to becoming the default option for patients who need an intervention to treat their aortic stenosis.
In honor of the 15th anniversary of TAVR, Cardiology Today’s Intervention has compiled a list of ten articles focusing on advances in TAVR in 2017.
PARTNER 2A, S3i: TAVR reduces cost, improves life expectancy in severe aortic stenosis
Patients with severe aortic stenosis and intermediate surgical risk who underwent TAVR with two different valves had lower long-term costs and a greater quality-adjusted life expectancy compared with those who underwent surgical AVR, according to data from two trials presented at TCT 2017.
Societies issue appropriate use criteria for severe aortic stenosis
Eleven professional societies have published a report to develop and evaluate appropriate use criteria for the treatment of patients with severe aortic stenosis.
The collaboration marks the first appropriate use criteria to address aortic stenosis, as well as the treatment options, including TAVR, available for patients.
TAVR outcomes comparable among two newer-generation valves
A study comparing novel self-expanding and balloon-expandable transcatheter heart valves determined that clinical and procedural results at 30 days were similar between two next-generation valves in patients undergoing TAVR.
Read More
FORWARD: Next-generation transcatheter heart valve safe, effective in older patients
TAVR performed with a next-generation system is clinically safe and effective in the treatment of older patients with severe aortic stenosis, according to the FORWARD study, published in the Journal of American College of Cardiology.
Kidney disease, injury predict poor outcomes after TAVR
Patients with chronic kidney disease or end-stage renal disease who underwent TAVR had an elevated risk for death, renal replacement therapy and worse outcomes, according to two studies published in JACC: Cardiovascular Interventions.
Newer self-expanding prosthesis associated with improved clinical success in TAVR
A newer-generation self-expanding prosthesis has been linked to improvements in clinical success for patients undergoing TAVR for aortic stenosis, according to data published in JACC: Cardiovascular Interventions.
The researchers also found the newer self-expanding prosthesis (Evolut R platform, Medtronic) was associated with a lower rate of mortality than Medtronic’s earlier-generation CoreValve prosthesis.
SURTAVI: TAVR noninferior to surgery in intermediate-risk patients
WASHINGTON — The SURTAVI trial met its primary endpoint demonstrating that TAVR with a self-expanding bioprosthesis was comparable to surgery for all-cause mortality or disabling stroke at 24 months, Michael J. Reardon, MD, reported at the American College of Cardiology Scientific Session.
TAVR may be favorable for women vs. surgical AVR
For women with high risk for complications, TAVR may be a better option compared with surgical AVR, according to a study published in Catheterization and Cardiovascular Interventions.
However, higher costs and increased risk of need for extracorporeal membrane oxygen should be considered, researchers wrote.
Subclinical leaflet thrombosis more common with TAVR vs. surgical AVR
WASHINGTON — Subclinical leaflet thrombosis occurred at a rate of about 12% in patients who received bioprosthetic valves and was significantly more common among patients who underwent transcatheter, as compared with surgical, aortic valve replacement, Raj R. Makkar, MD, reported at the American College of Cardiology Scientific Session.
In an analysis of data from the RESOLVE and SAVORY registries, Makkar, associate director of Cedars-Sinai Heart Institute, and colleagues sought to learn more about the prevalence of subclinical leaflet thrombosis and its effects on patients undergoing TAVR or surgical AVR.
ARTE: Aspirin regimen confers fewer major adverse events after TAVR vs. DAPT
Compared with dual antiplatelet therapy with clopidogrel and aspirin, single antiplatelet therapy with aspirin reduced the incidence of major or life-threatening bleeding events after TAVR without increasing the risk for stroke or MI, according to results presented at EuroPCR.